Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified:
Official tariff path
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified:
Level: headingGeneral duty: Varies / see child provision
What does HTS 3002 cover?
This provision appears in the 2026 Harmonized Tariff Schedule of the United States under the following legal tariff hierarchy. A product must match the wording and applicable section or chapter notes before this code is used on an entry.
1Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified:
Based on USITC HTS 2026 Revision 12, published July 21, 2026. The general rate does not include every origin-specific program, Section 301 or 232 measure, antidumping or countervailing duty, quota, or other agency requirement.